Chardan Releases Industry Report Covering PharmaCyte Biotech
August 04 2015 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that Chardan Capital
Markets LLC, a privately held full service global investment bank
specializing in micro, small and mid-cap companies, issued an
Industry Update featuring PharmaCyte Biotech. The report can be
viewed at www.PharmaCyte.com/reports.
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, commented on the report saying, “We are very
pleased with Chardan’s update of our efforts at PharmaCyte Biotech.
As noted in the report, we expect to be fully underway in three
clinical trials involving pancreatic cancer and its related
symptoms during the first quarter of 2016. These trials consist of
a Phase 2b clinical trial in Australia in which our pancreatic
cancer treatment will be compared to the current gold standard for
the treatment of pancreatic cancer and two clinical trials in the
U.S. that deal with the unbearable pain and the accumulation of
malignant ascites fluid resulting from advanced pancreatic cancer
and other solid abdominal tumors. Our plans are to begin the
clinical trials by the fourth quarter of 2015 and possibly sooner,
but the start date for the clinical trials will depend upon
regulatory approval of Austrianova’s cGMP encapsulation facility in
Bangkok, Thailand. That is the facility where our genetically
modified living cells will be encapsulated using the Cell-in-a-Box®
technology.”
Chardan Capital’s Senior Research Analyst in
Healthcare, Keay Nakae, CFA, authored the report, titled, “PMCB:
Intriguing Platform for Delivering Targeted Therapies.” The report
focuses on PharmaCyte Biotech’s encapsulation technology,
Cell-in-a-Box®, and its cancer and diabetes portfolios.
Mr. Nakae has over 15 years of experience
as a sell-side research analyst covering healthcare companies. He
previously worked at Ascendiant Capital, Collins Stewart/CE
Unterberg Towbin and Wedbush Morgan Securities. During his career
as an equity research analyst, Mr. Nakae has covered small- to
large-cap biotechnology, medical device and diagnostic companies
that compete in areas of cardiology, gynecology, neurology,
urology, oncology, diabetes, aesthetics and cardiac and spine
surgery. He has made numerous media appearances on Bloomberg TV and
has been quoted in publications such as The Wall Street Journal,
Time, Business Week and the Los Angeles Times. Mr. Nakae has also
been recognized by Forbes magazine in its annual survey of
America's Best Analysts.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company focused on developing and
preparing to commercialize treatments for cancer and diabetes based
upon a proprietary cellulose-based live-cell encapsulation
technology known as “Cell-in-a-Box®.” This unique and patented
technology will be used as a platform upon which treatments for
several types of cancer, including advanced, inoperable pancreatic
cancer and its related symptoms, as well as diabetes are being
developed.
PharmaCyte Biotech’s treatment for pancreatic
cancer involves encapsulating genetically modified human cells that
convert the prodrug ifosfamide into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to the
tumor as possible to enable the delivery of the highest levels of
the cancer-killing drug at the source of the cancer. Ifosfamide is
then given intravenously at one-third the normal dose to eliminate
the side effects normally associated with chemotherapy. When the
ifosfamide comes in contact with the encapsulated live cells
through the circulatory system, the activation of ifosfamide takes
place at or near the tumor. This “targeted chemotherapy” has proven
remarkably effective and safe to use in past clinical trials.
PharmaCyte Biotech is also developing treatments
for cancer based upon the encapsulation of chemical constituents of
the Cannabis plant. It is examining ways to exploit the benefits of
the Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of Cannabis, while at the same time minimizing or
outright eliminating the debilitating side effects often associated
with cancer treatments.
In addition to developing treatments for
pancreatic and other cancers, PharmaCyte Biotech is developing a
treatment for Type 1 diabetes and Type 2 insulin-dependent
diabetes. PharmaCyte Biotech plans to encapsulate a human cell line
which has been genetically engineered to produce, store and secrete
insulin on demand at levels in proportion to the levels of blood
sugar in the human body. The encapsulation of the insulin producing
live cells will be done using the Cell-in-a-Box® technology.
About Chardan Capital Markets,
LLCChardan Capital Markets is an international investment
bank headquartered in New York City, with offices in Los Angeles,
Sydney and Beijing. Chardan provides a wide array of financial
services, including investment banking, capital markets,
international trading and equity research. The investment banking
group focuses on providing banking and advisory services to private
and public companies in small and mid-cap markets. The
institutional coverage of Chardan Capital Markets spans North
America, Europe and Asia. Chardan Capital Markets is a registered
broker-dealer with the U.S. Securities and Exchange Commission and
is a member of the Financial Industry Regulatory Authority (FINRA),
the Municipal Securities Rulemaking Board (MSRB), the Securities
Insurance Protection Corporation (SIPC), the NASDAQ Stock Market
and the New York Stock Exchange. To learn more about Chardan
Capital Markets, visit www.chardancm.com.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte Biotech’s
ability to continue as a going concern, delays or unsuccessful
results in preclinical and clinical trials, flaws or defects
regarding its product candidates, changes in relevant legislation
or regulatory requirements, uncertainty of protection of PharmaCyte
Biotech’s intellectual property and PharmaCyte Biotech’s continued
ability to raise capital. PharmaCyte Biotech does not assume any
obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com